Publications

Boyce M, Moore AR, Sagatun L, Parsons BN, Varro A, Campbell F, Fossmark R, Waldum HL, Pritchard DM. Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol; published online October 2016.

Boyce M, van den Berg D, Mitchell T, Darwin K, Warrington S. Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia:  evidence against rebound hyperacidity. Eur J Clin Pharmacol 2016; DOI 10.1007/s00228-016-2150-x

Sagatun L, Mjønes P, Jianu CS, Boyce M, Waldum HL, Fossmark R. The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment.  Eur J Gastroenterol Hepatol; 2016; 28: 1345–1352.

Boyce M, Lloyd KA and Pritchard DM. Potential clinical indications for a CCK2 receptor antagonist.  Curr Opin Pharmacol 2016; 31:  63–75.

Lee Y, Urbanska AM, Wang H, Hayakawa Y, Au AS, Luna AM, Cheng W, Jin G, Bhagat G, Abrams JA, Friedman RA, Varro A, Wang KK, Boyce M, Rustgi AK, Quante M, Sepulveda AR, Wang TC. Gastrin stimulates a Cholecystokinin-2-Receptor-expressing cardia progenitor cell and promotes progression of Barrett’s-like esophagus. Oncotarget; 2016 Jul 18. doi: 10.18632/oncotarget.10667.

Aasarød K, Ramezanzadehkoldeh M , Shabestari M, Mosti M, Stunes A, Reseland J, Beisvåg V, Eriksen E, Sandvik A, Boyce M, Skallerud B, Syversen U, Fossmark R. The gastrin/CCK2 receptor antagonist netazepide improves bone quality in H+/K+ATPase beta subunit KO mice. J Endocrinol 2016; 230: 251–262.

Lloyd KA, Moore AR, Parsons BN, O’Hara A, Boyce M, Dockray GJ, Varro A and Pritchard DM. Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27. Oncotarget 2016; doi 10.18632/oncotarget.9990.

Boyce M and Thomsen L. Gastric neuroendocrine tumours: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol 2015; 50: 550–559.

Boyce M, Dowen S, Turnbull G, van den Berg F, Zhao C-M, Chen D, Black JW. Effect of netazepide, a gastrin receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia: randomised controlled trial in healthy subjects.  Br J Clin Pharmacol 2015; 79: 744–755.

Moore A, Boyce M, Steele I, Campbell F, Varro A, Pritchard DM.  Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One 2013; 8: e76462.

Sordal Ø, Waldum H, Nordrum I, Boyce, M, Bergh K, Munkvold B, Qvigstad G. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.  Helicobacter 2013;18: 397–405.

Boyce M, Warrington S, Black JW. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.  Br J Clin Pharmacol 2013; 76: 689–698.

Boyce M, Warrington S. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.  Br J Clin Pharmacol 2013; 76: 680–688.

Webb DL, Rudholm-Feldreich T, Gillberg L, Halim MA, Theodorsson E, Sanger GJ, Campbell CA, Boyce M, Näslund E, Hellström PM.  The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.  Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 41–49.

Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.  Aliment Pharmacol Ther 2012; 36: 181–189.

Kidd M, Siddique Z, Drozdov I, Gustafsson B, Camp R, Black JW, Boyce M, Modlin I. The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL-cell hyperplasia and gastric carcinoid tumor development.  Regul Pept 2010; 162: 52–60.